INBX Inhibrx Biosciences Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: INBX

Price (delayed)

$91.92

Market cap

$1.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.39

Enterprise value

$1.37B

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 19
Highlights
The quick ratio has soared by 66% from the previous quarter and by 23% YoY
The company's net income has shrunk by 108% YoY but it rose by 7% QoQ
The EPS has plunged by 107% YoY but it has grown by 7% from the previous quarter
Inhibrx Biosciences's equity has shrunk by 122% YoY
The debt has soared by 70% YoY and by 69% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of INBX

INBX stock price

How has the Inhibrx Biosciences stock price performed over time
Intraday
-3.47%
1 week
-11.6%
1 month
-28.16%
1 year
607.08%
YTD
16.35%
QTD
36.72%

Financial performance

How have Inhibrx Biosciences's revenue and profit performed over time
Revenue
$1.3M
Gross profit
$1.3M
Operating income
-$123.05M
Net income
-$130.19M
Gross margin
100%
Net margin
-10,014.2%
The company's net income has shrunk by 108% YoY but it rose by 7% QoQ
The net margin has plunged by 101% YoY but it has grown by 7% from the previous quarter
The operating margin has soared by 94% YoY and by 9% from the previous quarter
INBX's operating income has soared by 59% YoY and by 9% QoQ

Price vs fundamentals

How does INBX's price correlate with its fundamentals

Growth

What is Inhibrx Biosciences's growth rate over time

Valuation

What is Inhibrx Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
1,101.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,052.17
The EPS has plunged by 107% YoY but it has grown by 7% from the previous quarter
Inhibrx Biosciences's equity has shrunk by 122% YoY
The P/S is 101% higher than the last 4 quarters average of 569.3

Efficiency

How efficient is Inhibrx Biosciences business performance
The ROE has plunged by 151% YoY and by 109% from the previous quarter
The company's return on assets has shrunk by 109% YoY
The ROS has plunged by 101% YoY but it has grown by 8% from the previous quarter
Inhibrx Biosciences's ROIC has plunged by 101% YoY but it has increased by 26% from the previous quarter

Dividends

What is INBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INBX.

Financial health

How did Inhibrx Biosciences financials performed over time
Inhibrx Biosciences's total assets is 10% lower than its total liabilities
The quick ratio has soared by 66% from the previous quarter and by 23% YoY
The current ratio has surged by 64% since the previous quarter and by 26% year-on-year
The debt to equity has plunged by 164% from the previous quarter
Inhibrx Biosciences's equity has shrunk by 122% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.